ATARA BIOTHERAPEUTICS, INC. Contract Liability (Deferred Revenue)
ATARA BIOTHERAPEUTICS, INC. (ATRA) had Contract Liability (Deferred Revenue) of $77.83 million as of 2023-12-31, per its 10-K filed 2024-03-28.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2024-03-28
- 2023-12-31: Contract with Customer, Liability, Current $77.83M.
- 2021-09-30: Contract with Customer, Liability, Current $31.23M.
- 2021-06-30: Contract with Customer, Liability, Current $40.97M.
- 2021-03-31: Contract with Customer, Liability, Current $35.50M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2023-12-31 | $77.83M 10-K · filed 2024-03-28 |
| 2021-09-30 | $31.23M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $40.97M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $35.50M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $33.45M 10-Q · filed 2021-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |